KCAS Webinar: “Is Hybrid LC-MS/MS becoming the new Gold Standard?”

Originally produced by Xtalks on Friday, April 22, 2022 | 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)  60 min

 

Webinar Description:

 

Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays. However, we urge people to be open to a more flexible approach. Using hybrid LC-MS/MS can be an equally useful tool for quantitation of biological therapeutics and biomarkers where we combine the principles of ligand binding for extraction, enzymatic digestion and the powerful downstream selectivity of LC-MS/MS. Moreover, flexibility in surrogate peptide selection can be used to provide much more information about different regions of the molecule.  This combined with less need for “great” antibodies can help drive the drug development process. The presentation will focus on a number of applications to show how Hybrid LC-MS/MS can offer additional information to supplement analyte quantitation.

 

Speaker information:

John Perkins, PhD, Senior Scientific Advisor, KCAS Bioanalytical and Biomarker Services

 

John R. Perkins is the Senior Scientific Advisor with a focus on LC/MS technologies at KCAS. Previously, he was at Q2Solutions and legacy companies for over 24 years working in quantitative LC/MS, principally with small molecules. His primary focus was on validation and sample analysis processes as well as managing customer relationships in Ithaca NY. More recently he was responsible for the bioanalytical lab in Oss, The Netherlands.

 

John received his Ph.D. in Supercritical Fluid Chromatography/Mass Spectrometry from University of Wales, College of Cardiff, UK. He did postdoctoral research on nanoscale separation techniques with mass spectrometry at NIEHS in Research Triangle Park. He earned his Bachelors degree in Chemistry from University of Reading, UK and a Masters degree in Advanced Analytical Chemistry from University of Bristol, UK.

 

Dawn Dufield, PhD, Senior Director, Biopharmaceutical LC-MS/MS Services, KCAS Bioanalytical and Biomarker Services

 

Dawn R. Dufield is the Senior Director of Biopharmaceuticals (LC-MS/MS) Services at KCAS. Previously she had been with Pfizer and legacy companies for over 20 years working in the quantitative LC-MS/MS field. She was one of the early pioneers of using immunoaffinity combined with LC-MS/MS to offer additional selectivity which is now commonly referred to as Hybrid LCMS. She currently is a member of the AAPS Mass Spec Protein Bioanalysis Committee (MSPBC) and an active member of the American Society for Mass Spectrometry (ASMS). She has numerous publications and presentations in her field and recently contributed to a white paper on recommendations for validation of LCMS based bioanalytical methods for protein biotherapeutics.

 

Dawn received her Ph.D. in Bioanalytical Chemistry (Honors) from the University of Kansas in Lawrence, K. She earned her bachelor’s degree in Chemistry, (Computer minor) from Southwest Missouri State University in Springfield, MO.

 

Key takeaways:

The presentation will address…

  • Why might there be a need for Hybrid LC-MS/MS in large molecule quantitation?
  • Prinicpals of Hybrid LC-MS/MS
  • Advantages of Hybrid LC-MS/MS
  • Case Studies Illustrating the value of Hybrid LC-MS/MS

 

Audience summary:

Who should attend?

  • Pharma/Biopharma
  • CEO
  • Directors
  • Managers

 

If you’d like to hear more about our Hybrid capabilities, please Register Now for this webinar or contact KCAS using the form below.